17 completed, 6 unknown, 3 active not recruiting, 2 enrolling by invitation. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Completed 17, Unknown 6, Active not recruiting 3, Enrolling by invitation 2, Recruiting 1, Terminated 1 |
Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE) Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] - Eosinophilic Esophagitis (EoE) | Phase 4 | Recruiting | University of California, San Diego | 30 | 2024-11-10 | 2024-12-11 |
| Dupilumab for Eosinophilic Esophagitis With Severe Strictures Dupilumab - Eosinophilic Esophagitis, EoE | Phase 4 | Active not recruiting | University of North Carolina, Chapel Hill | 23 | 2024-05-16 | 2026-04-29 |
| BenRalizumab Effect on Airway Remodeling in Severe asTHma Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling | Phase 4 | Completed | Aristotle University Of Thessaloniki | 36 | 2024-03-01 | 2026-10-28 |
| A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) Dupilumab, Placebo - Eosinophilic Oesophagitis | Phase 4 | Active not recruiting | Sanofi | 69 | 2023-11-29 | 2026-09-30 |
| A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps dupilumab, mepolizumab - Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic | Phase 4 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 220 | 2023-04-27 | 2025-07-01 |
| BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Benralizumab - Asthma | Phase 4 | Completed | AstraZeneca | 45 | 2022-10-11 | 2025-03-25 |
| Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose - Eosinophilic Esophagitis | Phase 4 | Completed | Children's Hospital of Philadelphia | 21 | 2022-06-16 | 2025-11-10 |
| Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) Fluticasone Propionate, Budesonide - Eosinophilic Esophagitis | Phase 4 | Completed | University Hospitals Cleveland Medical Center | 23 | 2021-11-17 | 2024-11-07 |
| Predictive Signature of Benralizumab Response Benralizumab Prefilled Syringe - Asthma; Eosinophilic, Severe Asthma | Phase 4 | Completed | Nantes University Hospital | 85 | 2021-10-11 | 2026-11-13 |
| Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma Mepolizumab, Salbutamol - Asthma | Phase 4 | Completed | GlaxoSmithKline | 100 | 2021-06-29 | 2024-12-10 |
| Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma Reslizumab - Asthma; Eosinophilic | Phase 4 | Completed | McMaster University | 10 | 2021-02-10 | 2024-01-25 |
| Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Omeprazole 20mg BID - Eosinophilic Esophagitis | Phase 4 | Unknown | University of Colorado, Denver | 90 | 2020-10-07 | 2024-07-03 |
| A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Symbicort®, Fasenra®, Ventolin® - Asthma, Severe Eosinophilic Asthma | Phase 4 | Completed | AstraZeneca | 170 | 2020-07-27 | 2025-01-09 |
| Anti-viral Effects of Azithromycin in Patients With Asthma and COPD Azithromycin, Placebo oral tablet - Asthma, COPD | Phase 4 | Unknown | Bispebjerg Hospital | 100 | 2020-03-02 | 2021-07-26 |
| A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Mepolizumab 100 MG [Nucala] - Eosinophilic Asthma | Phase 4 | Unknown | University of Sao Paulo General Hospital | 18 | 2020-01-09 | 2020-01-14 |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Benralizumab, Placebo - Asthma | Phase 4 | Completed | AstraZeneca | 75 | 2019-10-08 | 2026-11-13 |
| Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". Mepolizumab, Omalizumab - Asthma, Eosinophilic Asthma | Phase 4 | Unknown | University of Newcastle, Australia | 200 | 2018-11-03 | 2020-10-14 |
| Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma Prednisolone, Placebo oral capsule - Asthma | Phase 4 | Completed | NHS Greater Glasgow and Clyde | 33 | 2018-10-19 | 2020-03-06 |
Showing 20 of 30. Sign in to see all of them.
Pulmonary Eosinophilia (18) · Asthma (15) · Eosinophilic Esophagitis (11) · Lung Diseases (3) · Esophagitis (2) · Inflammation (2) · Airway Remodeling (1) · Bronchial Diseases (1) · Chronic Disease (1) · Churg-Strauss Syndrome (1) · Constriction, Pathologic (1) · Deglutition Disorders (1) · Esophageal Diseases (1) · Gastroenteritis (1)
Hemic and Lymphatic Diseases (30) · Hematologic Diseases (29) · Leukocyte Disorders (29) · Hypersensitivity (26) · Hypersensitivity, Immediate (26) · Immune System Diseases (25) · Hypereosinophilic Syndrome (18) · Respiratory Tract Diseases (17) · Lung Diseases (15) · Respiratory Hypersensitivity (15) · Bronchial Diseases (14) · Lung Diseases, Obstructive (14) · Digestive System Diseases (11) · Esophageal Diseases (10)
benralizumab (6) · mepolizumab (6) · dupilumab (5) · Fluticasone (4) · Albuterol (3) · Budesonide (3) · BID protein, human (2) · Omalizumab (2) · Omeprazole (2) · Prednisolone (2) · Azithromycin (1) · Biological Products (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Coal Tar (1) · Cromolyn Sodium (1)
AstraZeneca (3) · GlaxoSmithKline (2) · University of North Carolina, Chapel Hill (2) · Aristotle University Of Thessaloniki (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · Azienda Policlinico Umberto I (1) · Bispebjerg Hospital (1) · Children's Hospital of Philadelphia (1) · Claire Daniels (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dallas VA Medical Center (1) · Endeavor Health (1) · Hamamatsu University (1) · McMaster University (1) · NHS Greater Glasgow and Clyde (1)
United States (15) · United Kingdom (5) · Canada (4) · France (4) · Denmark (3) · Germany (3) · Italy (3) · Australia (2) · Belgium (2) · Brazil (2) · Spain (2) · Sweden (2) · Argentina (1) · Greece (1) · India (1)
Evan S Dellon, MD, MPH (2) · Celeste Porsbjerg, MD, PhD (1) · Christian Pedersen, MD (1) · Christian von Buchwald (1) · Dr. David Jackson (1) · Giselle Mosnaim, MD, MS (1) · Ian Pavord (1) · Jay A Lieberman, MD (1) · Jonathan Spergel, MD, PhD (1) · Kalliopi Domvri, Dr (1) · Kingo Chida, MD, PhD (1) · Marek Lommatzsch, MD (1) · Mario Castro, MD (1)
PMID 10049409, PMID 12045120, PMID 16329022, PMID 17919504, PMID 20920599, PMID 21037369, PMID 23567357, PMID 25614171, PMID 25858909, PMID 26142551, PMID 26247167, PMID 26426817, PMID 26513622, PMID 26685124, PMID 28461289, PMID 29221581, PMID 29544738, PMID 30009819, PMID 30708107, PMID 30872104, PMID 31499249, PMID 31657082, PMID 31798645, PMID 32762056, PMID 33009060, PMID 33369570, PMID 33971856, PMID 37131265, PMID 37343842, PMID 38071986, PMID 41038415, PMID 41084592, PMID 42458446, PMID 42861971
2015 (1), 2018 (1), 2019 (1), R01DK101856 (1)